Jeffrey A Meckler
CIK 1506916 · Co-Chief Executive Officer · last filed 2026-09-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TVTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVTX | Director | 101,500 | $53.27 | $5.41M | -$2.27M | 9 | 2026-09-11 |
| INDP | Co-Chief Executive Officer | 229,929 | $2.21 | $508.1K | $273.6K | 17 | 2026-02-13 |
| Intec Pharma Ltd. (NTEC) Delisted | Chief Executive Officer | 9,838 | $9.63 | $94.7K | $59.3K | 4 | 2020-07-17 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 64,000 | — | — | $350.1K | 10 | 2020-05-19 |
| QLTI | Director | 94,500 | $26.88 | $2.54M | $362.0K | 10 | 2016-06-21 |
Recent Filings · Page 3 of 6
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-09-12 | INDP | Buy (P) | +10,308 | $28.9K | EDGAR |
| 2022-09-08 | INDP | Buy (P) | +9,692 | $24.8K | EDGAR |
| 2022-06-07 | INDP | Buy (P) | +19,727 | $51.9K | EDGAR |
| 2022-05-12 | TVTX | Grant (A) | +3,000 | $0 | EDGAR |
| 2022-01-28 | INDP | Grant (A) | — | $0 | EDGAR |
| 2021-11-19 | INDP | Buy (P) | +11,187 | $65.1K | EDGAR |
| 2021-09-16 | INDP | Buy (P) | +12,000 | $84.0K | EDGAR |
| 2021-08-06 | INDP | Grant (A) | — | $0 | EDGAR |
| 2021-05-18 | TVTX | Grant (A) | +3,000 | $0 | EDGAR |
| 2020-07-17 | Intec Pharma Ltd. (NTEC) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.